Prediction of drug-ABC-transporter interaction - Recent advances and future challenges

Advanced Drug Delivery Reviews

Volumn 86, Issue , 2015, Pages 17-26

  Montanari, Floriane ^a   Ecker, Gerhard F ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

ABC transporters; Bioassays; Computational models; Machine learning; Pharmacophore modeling; Transport inhibition

Indexed keywords

BIOASSAY; BIOCHEMISTRY; BLOOD; GLYCOPROTEINS; LEARNING SYSTEMS;

ABC TRANSPORTER; BLOOD-BRAIN BARRIER; COMPUTATIONAL MODEL; DEFENSE MECHANISM; DRUG DISCOVERY PROCESS; INTRACELLULAR ACCUMULATION; PHARMACOPHORE MODELING; STRUCTURE-BASED DESIGNS;

DRUG INTERACTIONS;

ABC TRANSPORTER; DIGOXIN; DRONEDARONE; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN; QUINIDINE; RANOLAZINE; RIFAMPICIN; RITONAVIR; SAQUINAVIR; TIPRANAVIR; TOPOTECAN; DRUG; LIGAND;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; COMPUTER MODEL; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG HALF LIFE; DUBIN JOHNSON SYNDROME; HUMAN; INTESTINE; LIVER TOXICITY; MACHINE LEARNING; NONHUMAN; PHARMACOPHORE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; ANIMAL; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; METABOLISM;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; HUMANS; LIGANDS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS;

EID: 84937628052     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.03.001     Document Type: Review

References (86)

1. Vasiliou V., Vasiliou K., Nebert D.W. Human ATP-binding cassette (ABC) transporter family. Hum. Genet. 2009, 3:281-290. 10.1186/1479-7364-3-3-281.
2. Tarling E.J., de Aguiar Vallim T.Q., Edwards P.A. Role of ABC transporters in lipid transport and human disease. Trends Endocrinol. Metab. 2013, 24:342-350. 10.1016/j.tem.2013.01.006.
3. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta Biomembr. 1976, 455:152-162. 10.1016/0005-2736(76)90160-7.
4. Chatterjee M., Robson C.N., Harris A.L. Reversal of multidrug resistance by verapamil and modulation by alpha 1-acid glycoprotein in wild-type and multidrug-resistant Chinese hamster ovary cell lines. Cancer Res. 1990, 50:2818-2822.
5. Lehnert M., Dalton W.S., Roe D., Emerson S., Salmon S.E. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood 1991, 77:348-354.
6. Gray A.J.G., Groth P., Loizou A., Askjaer S., Brenninkmeijer C., Burger K., et al. Applying linked data approaches to pharmacology: architectural decisions and implementation. Semantic Web. 2014, 5:101-113. 10.3233/SW-2012-0088.
7. Kalvass J.C., Polli J.W., Bourdet D.L., Feng B., Huang S.-M., Liu X., et al. Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position. Clin. Pharmacol. Ther. 2013, 94:80-94. 10.1038/clpt.2013.34.
8. Food and Drug Administration Guidance for Industry Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations 2012, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf accessed January 20, 2014).
9. Wu C.-Y., Benet L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a Biopharmaceutics Drug Disposition Classification System. Pharm. Res. 2005, 22:11-23. 10.1007/s11095-004-9004-4.
10. Demeule M., Régina A., Jodoin J., Laplante A., Dagenais C., Berthelet F., et al. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vasc. Pharmacol. 2002, 38:339-348.
11. Laquintana V., Trapani A., Denora N., Wang F., Gallo J.M., Trapani G. New strategies to deliver anticancer drugs to brain tumors. Expert Opin. Drug Deliv. 2009, 6:1017-1032. 10.1517/17425240903167942.
12. Durmus S., Sparidans R.W., van Esch A., Wagenaar E., Beijnen J.H., Schinkel A.H. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699). Pharm. Res. 2014, 1-10. 10.1007/s11095-014-1442-z.
13. Durmus S., Xu N., Sparidans R.W., Wagenaar E., Beijnen J.H., Schinkel A.H. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387. Pharmacol. Res. 2013, 76:9-16. 10.1016/j.phrs.2013.06.009.
14. Bagal S.K., Bungay P.J. Minimizing drug exposure in the CNS while maintaining good oral absorption. ACS Med. Chem. Lett. 2012, 3:948-950. 10.1021/ml300378n.
15. Sanchez-Covarrubias L., Slosky L.M., Thompson B.J., Zhang Y., Laracuente M.-L., DeMarco K.M., et al. P-glycoprotein modulates morphine uptake into the CNS: a role for the non-steroidal anti-inflammatory drug diclofenac. PLoS ONE 2014, 9:e88516. 10.1371/journal.pone.0088516.
16. Cuperus F.J.C., Claudel T., Gautherot J., Halilbasic E., Trauner M. The role of canalicular ABC transporters in cholestasis. Drug Metab. Dispos. 2014, 42:546-560. 10.1124/dmd.113.056358.
17. Wlcek K., Stieger B. ATP-binding cassette transporters in liver. BioFactors 2014, 40:188-198. 10.1002/biof.1136.
18. Dawson S., Stahl S., Paul N., Barber J., Kenna J.G. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab. Dispos. 2012, 40:130-138. 10.1124/dmd.111.040758.
19. Andress E.J., Nicolaou M., Romero M.R., Naik S., Dixon P.H., Williamson C., et al. Molecular mechanistic explanation for the spectrum of cholestatic disease caused by the S320F variant of ABCB4. Hepatology 2014, 59:1921-1931. 10.1002/hep.26970.
20. Gadsby D.C., Vergani P., Csanady L. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 2006, 440:477-483. 10.1038/nature04712.
21. Machida I., Wakusawa S., Sanae F., Hayashi H., Kusakabe A., Ninomiya H., et al. Mutational analysis of the MRP2 gene and long-term follow-up of Dubin-Johnson syndrome in Japan. J. Gastroenterol. 2005, 40:366-370. 10.1007/s00535-004-1555-y.
22. Cameron J., Ranheim T., Halvorsen B., Kulseth M.A., Leren T.P., Berge K.E. Tangier disease caused by compound heterozygosity for ABCA1 mutations R282X and Y1532C. Atherosclerosis 2010, 209:163-166. 10.1016/j.atherosclerosis.2009.08.039.
23. Matsuo H., Takada T., Ichida K., Nakamura T., Nakayama A., Suzuki H., et al. ABCG2/BCRP dysfunction as a major cause of gout. Nucleosides Nucleotides Nucleic Acids 2011, 30:1117-1128. 10.1080/15257770.2011.633954.
24. Abuznait A.H., Kaddoumi A. Role of ABC transporters in the pathogenesis of Alzheimer's disease. ACS Chem. Neurosci. 2012, 3:820-831. 10.1021/cn300077c.
25. Greiner B., Eichelbaum M., Fritz P., Kreichgauer H.-P., von Richter O., Zundler J., et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 1999, 104:147-153.
26. Choo E.F., Leake B., Wandel C., Imamura H., Wood A.J.J., Wilkinson G.R., et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos. 2000, 28:655-660.
27. Umeyama Y., Fujioka Y., Okuda T. Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information. Xenobiotica 2014, 44:1135-1144. 10.3109/00498254.2014.928958.
28. Conseil G., Baubichon-Cortay H., Dayan G., Jault J.M., Barron D., Di Pietro A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:9831-9836.
29. Comte G., Daskiewicz J.B., Bayet C., Conseil G., Viornery-Vanier A., Dumontet C., et al. C-isoprenylation of flavonoids enhances binding affinity toward P-glycoprotein and modulation of cancer cell chemoresistance. J. Med. Chem. 2001, 44:763-768.
30. Wesołowska O., Wiśniewski J., Środa K., Krawczenko A., Bielawska-Pohl A., Paprocka M., et al. 8-Prenylnaringenin is an inhibitor of multidrug resistance-associated transporters, P-glycoprotein and MRP1. Eur. J. Pharmacol. 2010, 644:32-40. 10.1016/j.ejphar.2010.06.069.
31. Tan K.W., Li Y., Paxton J.W., Birch N.P., Scheepens A. Identification of novel dietary phytochemicals inhibiting the efflux transporter breast cancer resistance protein (BCRP/ABCG2). Food Chem. 2013, 138:2267-2274. 10.1016/j.foodchem.2012.12.021.
32. Gurley B.J., Swain A., Williams D.K., Barone G., Battu S.K. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol. Nutr. Food Res. 2008, 52:772-779. 10.1002/mnfr.200700081.
33. Chang C., Swaan P.W. Computational approaches to modeling drug transporters. Eur. J. Pharm. Sci. 2006, 27:411-424. 10.1016/j.ejps.2005.09.013.
34. Chen L., Li Y., Yu H., Zhang L., Hou T. Computational models for predicting substrates or inhibitors of P-glycoprotein. Drug Discov. Today 2012, 17:343-351. 10.1016/j.drudis.2011.11.003.
35. Ecker G.F., Stockner T., Chiba P. Computational models for prediction of interactions with ABC-transporters. Drug Discov. Today 2008, 13:311-317. 10.1016/j.drudis.2007.12.012.
36. Chang C., Ekins S., Bahadduri P., Swaan P.W. Pharmacophore-based discovery of ligands for drug transporters. Adv. Drug Deliv. Rev. 2006, 58:1431-1450. 10.1016/j.addr.2006.09.006.
37. Demel M.A., Krämer O., Ettmayer P., Haaksma E.E.J., Ecker G.F. Predicting ligand interactions with ABC transporters in ADME. Chem. Biodivers. 2009, 6:1960-1969. 10.1002/cbdv.200900138.
38. Gandhi Y.A., Morris M.E. Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2). AAPS J. 2009, 11:541-552. 10.1208/s12248-009-9132-1.
39. Jabeen I., Pleban K., Rinner U., Chiba P., Ecker G.F. Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein. J. Med. Chem. 2012, 55:3261-3273. 10.1021/jm201705f.
40. Broccatelli F., Carosati E., Neri A., Frosini M., Goracci L., Oprea T.I., et al. A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. J. Med. Chem. 2011, 54:1740-1751. 10.1021/jm101421d.
41. Chen L., Li Y., Zhao Q., Peng H., Hou T. adme evaluation in drug discovery. 10. Predictions of P-glycoprotein inhibitors using recursive partitioning and naive bayesian classification techniques. Mol. Pharm. 2011, 8:889-900. 10.1021/mp100465q.
42. Chiba P., Annibali D., Hitzler M., Richter E., Ecker G. Studies on propafenone-type modulators of multidrug resistance VI. Synthesis and pharmacological activity of compounds with varied spacer length between the central aromatic ring and the nitrogen atom. Il Farm. 1998, 53:357-364. 10.1016/S0014-827X(98)00035-4.
43. Montanari F., Ecker G.F. BCRP inhibition: from data collection to ligand-based modeling. Mol. Inform. 2014, 33:322-331. 10.1002/minf.201400012.
44. Warner D.J., Chen H., Cantin L.-D., Kenna J.G., Stahl S., Walker C.L., et al. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug Metab. Dispos. 2012, 40:2332-2341. 10.1124/dmd.112.047068.
45. Pedersen J.M., Matsson P., Bergström C.A.S., Norinder U., Hoogstraate J., Artursson P. Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J. Med. Chem. 2008, 51:3275-3287. 10.1021/jm7015683.
46. Palmeira A., Rodrigues F., Sousa E., Pinto M., Vasconcelos M.H., Fernandes M.X. New uses for old drugs: pharmacophore-based screening for the discovery of P-glycoprotein inhibitors. Chem. Biol. Drug Des. 2011, 78:57-72. 10.1111/j.1747-0285.2011.01089.x.
47. Pan Y., Chothe P.P., Swaan P.W. Identification of novel breast cancer resistance protein (BCRP) inhibitors by virtual screening. Mol. Pharm. 2013, 10:1236-1248. 10.1021/mp300547h.
48. Ritschel T., Hermans S.M.A., Schreurs M., van den Heuvel J.J.M.W., Koenderink J.B., Greupink R., et al. In silico identification and in vitro validation of potential cholestatic compounds through 3D ligand-based pharmacophore modeling of BSEP inhibitors. Chem. Res. Toxicol. 2014, 27:873-881. 10.1021/tx5000393.
49. Zhang H., Xiang M.-L., Zhao Y.-L., Wei Y.-Q., Yang S.-Y. Support vector machine and pharmacophore-based prediction models of multidrug-resistance protein 2 (MRP2) inhibitors. Eur. J. Pharm. Sci. 2009, 36:451-457. 10.1016/j.ejps.2008.11.014.
50. Li D., Chen L., Li Y., Tian S., Sun H., Hou T. ADMET evaluation in drug discovery. 13. Development of in silico prediction models for P-glycoprotein substrates. Mol. Pharm. 2014, 11:716-726. 10.1021/mp400450m.
51. Wang Z., Chen Y., Liang H., Bender A., Glen R.C., Yan A. P-glycoprotein substrate models using support vector machines based on a comprehensive data set. J. Chem. Inf. Model. 2011, 51:1447-1456. 10.1021/ci2001583.
52. Hazai E., Hazai I., Ragueneau-Majlessi I., Chung S.P., Bikadi Z., Mao Q. Predicting substrates of the human breast cancer resistance protein using a support vector machine method. BMC Bioinformatics 2013, 14:130. 10.1186/1471-2105-14-130.
53. Pinto M., Trauner M., Ecker G.F. An in silico classification model for putative ABCC2 substrates. Mol. Inform. 2012, 31:547-553. 10.1002/minf.201200049.
54. Szakács G., Annereau J.-P., Lababidi S., Shankavaram U., Arciello A., Bussey K.J., et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004, 6:129-137. 10.1016/j.ccr.2004.06.026.
55. Matsson P., Pedersen J.M., Norinder U., Bergström C.A.S., Artursson P. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm. Res. 2009, 26:1816-1831. 10.1007/s11095-009-9896-0.
56. Bento A.P., Gaulton A., Hersey A., Bellis L.J., Chambers J., Davies M., et al. The ChEMBL bioactivity database: an update. Nucleic Acids Res. 2014, 42:D1083-D1090. 10.1093/nar/gkt1031.
57. Wang Y., Xiao J., Suzek T.O., Zhang J., Wang J., Zhou Z., et al. PubChem's bioassay database. Nucleic Acids Res. 2012, 40:D400-D412. 10.1093/nar/gkr1132.
58. Zdrazil B., Pinto M., Vasanthanathan P., Williams A.J., Balderud L.Z., Engkvist O., et al. Annotating human P-glycoprotein bioassay data. Mol. Inform. 2012, 31:599-609. 10.1002/minf.201200059.
59. Bentz J., O'Connor M.P., Bednarczyk D., Coleman J., Lee C., Palm J., et al. Variability in P-glycoprotein inhibitory potency (IC50) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria. Drug Metab. Dispos. 2013, 41:1347-1366. 10.1124/dmd.112.050500.
60. Balimane P.V., Marino A., Chong S. P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate?. AAPS J. 2008, 10:577-586. 10.1208/s12248-008-9068-x.
61. Giri N., Agarwal S., Shaik N., Pan G., Chen Y., Elmquist W.F. Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design. Drug Metab. Dispos. 2009, 37:560-570. 10.1124/dmd.108.022046.
62. Shintre C.A., Pike A.C.W., Li Q., Kim J.-I., Barr A.J., Goubin S., et al. Structures of ABCB10, a human ATP-binding cassette transporter in apo- and nucleotide-bound states. Proc. Natl. Acad. Sci. 2013, 110:9710-9715. 10.1073/pnas.1217042110.
63. Bernstein F.C., Koetzle T.F., Williams G.J., Meyer E.F., Brice M.D., Rodgers J.R., et al. The Protein Data Bank: a computer-based archival file for macromolecular structures. J. Mol. Biol. 1977, 112:535-542.
64. Jin M.S., Oldham M.L., Zhang Q., Chen J. Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature 2012, 490:566-569. 10.1038/nature11448.
65. Aller S.G., Yu J., Ward A., Weng Y., Chittaboina S., Zhuo R., et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009, 323:1718-1722. 10.1126/science.1168750.
66. Ward A.B., Szewczyk P., Grimard V., Lee C.-W., Martinez L., Doshi R., et al. Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain. Proc. Natl. Acad. Sci. 2013, 110:13386-13391. 10.1073/pnas.1309275110.
67. Li J., Jaimes K.F., Aller S.G. Refined structures of mouse P-glycoprotein. Protein Sci. 2014, 23:34-46. 10.1002/pro.2387.
68. Dawson R.J.P., Locher K.P. Structure of the multidrug ABC transporter Sav 1866 from Staphylococcus aureus in complex with AMP-PNP. FEBS Lett. 2007, 581:935-938. 10.1016/j.febslet.2007.01.073.
69. Dawson R.J.P., Locher K.P. Structure of a bacterial multidrug ABC transporter. Nature 2006, 443:180-185. 10.1038/nature05155.
70. Ward A., Reyes C.L., Yu J., Roth C.B., Chang G. Flexibility in the ABC transporter MsbA: alternating access with a twist. Proc. Natl. Acad. Sci. 2007, 104:19005-19010. 10.1073/pnas.0709388104.
71. Hohl M., Briand C., Grütter M.G., Seeger M.A. Crystal structure of a heterodimeric ABC transporter in its inward-facing conformation. Nat. Struct. Mol. Biol. 2012, 19:395-402. 10.1038/nsmb.2267.
72. McDevitt C.A., Callaghan R. How can we best use structural information on P-glycoprotein to design inhibitors?. Pharmacol. Ther. 2007, 113:429-441. 10.1016/j.pharmthera.2006.10.003.
73. Dolghih E., Bryant C., Renslo A.R., Jacobson M.P. Predicting binding to P-glycoprotein by flexible receptor docking. PLoS Comput. Biol. 2011, 7:e1002083. 10.1371/journal.pcbi.1002083.
74. Mahar Doan K.M., Humphreys J.E., Webster L.O., Wring S.A., Shampine L.J., Serabjit-Singh C.J., et al. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 2002, 303:1029-1037. 10.1124/jpet.102.039255.
75. Klepsch F., Chiba P., Ecker G.F. Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of P-glycoprotein. PLoS Comput. Biol. 2011, 7:e1002036. 10.1371/journal.pcbi.1002036.
76. Klepsch F., Vasanthanathan P., Ecker G.F. Ligand and structure-based classification models for prediction of P-glycoprotein inhibitors. J. Chem. Inf. Model. 2014, 54:218-229. 10.1021/ci400289j.
77. Ferreira R.J., Ferreira M.-J.U., dos Santos D.J.V.A. Molecular docking characterizes substrate-binding sites and efflux modulation mechanisms within P-glycoprotein. J. Chem. Inf. Model. 2013, 53:1747-1760. 10.1021/ci400195v.
78. Ferreira R.J., Ferreira M.-J.U., dos Santos D.J.V.A. Insights on P-glycoprotein's efflux mechanism obtained by molecular dynamics simulations. J. Chem. Theory Comput. 2012, 8:1853-1864. 10.1021/ct300083m.
79. Ferreira R.J., dos Santos D.J.V.A., Ferreira M.-J.U., Guedes R.C. Toward a better pharmacophore description of P-glycoprotein modulators, based on macrocyclic diterpenes from Euphorbia species. J. Chem. Inf. Model. 2011, 51:1315-1324. 10.1021/ci200145p.
80. Kim J., Wu S., Tomasiak T.M., Mergel C., Winter M.B., Stiller S.B., et al. Subnanometre-resolution electron cryomicroscopy structure of a heterodimeric ABC exporter. Nature 2014, 517:396-400. (advance online, publication).
81. Wen P.-C., Verhalen B., Wilkens S., Mchaourab H.S., Tajkhorshid E. On the origin of large flexibility of P-glycoprotein in the inward-facing state. J. Biol. Chem. 2013, 288:19211-19220. 10.1074/jbc.M113.450114.
82. Rauch C., Paine S.W., Littlewood P. Can long range mechanical interaction between drugs and membrane proteins define the notion of molecular promiscuity? Application to P-glycoprotein-mediated multidrug resistance (MDR). Biochim. Biophys. Acta Gen. Subj. 2013, 1830:5112-5118. 10.1016/j.bbagen.2013.06.038.
83. Copeland R.A., Pompliano D.L., Meek T.D. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 2006, 5:730-739. 10.1038/nrd2082.
84. Clay A.T., Sharom F.J. Lipid bilayer properties control membrane partitioning, binding, and transport of p-glycoprotein substrates. Biochemistry (Mosc) 2013, 52:343-354. 10.1021/bi301532c.
85. Sedykh A., Fourches D., Duan J., Hucke O., Garneau M., Zhu H., et al. Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm. Res. 2013, 30:996-1007. 10.1007/s11095-012-0935-x.
86. Michl J., Scharinger C., Zauner M., Kasper S., Freissmuth M., Sitte H.H., et al. A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities. Eur. Neuropsychopharmacol. 2014, 24:1463-1474. 10.1016/j.euroneuro.2014.06.013.